Holen Sie sich die Stockscreener-App
18.48
1.48%
0.53
Schlusskurs vom Vortag:
$17.95
Offen:
$18.23
24-Stunden-Volumen:
104.32K
Relative Volume:
0.35
Marktkapitalisierung:
$1.25B
Einnahmen:
$-9,000
Nettoeinkommen (Verlust:
$-68.03M
KGV:
-17.60
EPS:
-1.05
Netto-Cashflow:
$-44.76M
1W Leistung:
-5.18%
1M Leistung:
+20.55%
6M Leistung:
+20.07%
1J Leistung:
+2.50%
1-Tages-Spanne:
$17.95
$18.95
1-Wochen-Bereich:
$17.46
$19.63
52-Wochen-Spanne:
$12.56
$26.30
Pulse Biosciences Inc Stock (PLSE) Company Profile
Firmenname
Pulse Biosciences Inc
Sektor
Telefon
510-906-4600
Adresse
3957 POINT EDEN WAY, HAYWARD, CA
Compare PLSE vs ISRG, BDX, ALC, RMD, MDLN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
18.47 | 1.22B | -9,000 | -68.03M | -44.76M | -1.05 |
|
ISRG
Intuitive Surgical Inc
|
504.60 | 176.65B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
171.32 | 49.56B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
83.73 | 40.50B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
258.41 | 37.63B | 5.40B | 1.49B | 1.78B | 10.12 |
|
MDLN
Medline Inc
|
43.30 | 36.02B | 28.43B | 1.16B | 1.26B | 1.4457 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Eingeleitet | Mizuho | Outperform |
| 2025-07-07 | Eingeleitet | Oppenheimer | Outperform |
| 2021-07-27 | Eingeleitet | Stephens | Overweight |
| 2021-03-11 | Eingeleitet | Maxim Group | Buy |
| 2021-01-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-12 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-02-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2019-02-25 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Pulse Biosciences Inc Aktie (PLSE) Neueste Nachrichten
Thyroid experts review 15–22 month data on Pulse nPulse ablation - Stock Titan
Pulse Biosciences Highlights nPulse Cardiac Ablation Progress - TipRanks
Pulse Biosciences posts updated investor deck highlighting nPulse cardiac catheter and strengthened EP focus - TradingView
Pulse Biosciences (NASDAQ: PLSE) releases updated March 2026 investor deck - Stock Titan
Pulse Biosciences, Inc (PLSE) Stock Analysis: Is A 59% Upside Within Reach? - DirectorsTalk Interviews
Market Wrap: Does Pulse Biosciences Inc have strong fundamentalsWeekly Earnings Recap & Weekly Top Stock Performers List - baoquankhu1.vn
Understanding the Setup: (PLSE) and Scalable Risk - Stock Traders Daily
Pulse Biosciences (PLSE) clarifies disclosure on CCO Kevin Danahy’s resignation - Stock Titan
Pulse Biosciences Executive Sells 60,000 Shares - TradingView
Is Pulse Biosciences (PLSE) Pricing Make Sense After Recent Volatility And Cash Flow Forecasts? - Yahoo Finance
Pulse Biosciences (PLSE) Is Down 12.6% After Wider Losses And New Funding PlansHas The Bull Case Changed? - simplywall.st
PLSE Should I Buy - Intellectia AI
Pulse Biosciences chief commercial officer resigns effective immediately - Investing.com
Pulse Biosciences Announces Resignation of Chief Commercial Officer - TipRanks
Chief Commercial Officer exits Pulse Biosciences (PLSE) with no stated dispute - Stock Titan
US med-tech companies bullish about 2026 - BioWorld MedTech
Is Pulse Biosciences (PLSE) Share Price Justified After Recent Volatility In Healthcare Sentiment - simplywall.st
Pulse Biosciences (PLSE) Price Target Increased by 27.66% to 30.60 - Nasdaq
Pulse Biosciences, Inc (PLSE) Stock Analysis: Exploring a 48.59% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
ETF Watch: Will Perfect Corp Equity Warrant face regulatory challenges2025 Stock Rankings & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Pulse Biosciences CCO Danahy sells $118k in PLSE stock By Investing.com - Investing.com Canada
Kevin Patrick Danahy Sells 5,000 Shares of Pulse Biosciences (NASDAQ:PLSE) Stock - MarketBeat
Pulse Biosciences (PLSE) CCO exercises options and sells 5,000 shares - Stock Titan
PLSE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 20, 2026 - BioSpace
Aug EndMonth: Is Pulse Biosciences Inc benefiting from innovation trendsTrade Entry Summary & Smart Swing Trading Techniques - baoquankhu1.vn
Pulse Biosciences (NASDAQ:PLSE) Rating Increased to Hold at Wall Street Zen - MarketBeat
MSN Money - MSN
Pulse Biosciences (NASDAQ:PLSE) Shares Down 6.5%Here's Why - MarketBeat
Pulse Biosciences Inc (PLSE) Shares Gap Down to $22.02 on Feb 20 - GuruFocus
Oppenheimer raises Pulse Biosciences stock price target to $30 By Investing.com - Investing.com Canada
Pulse Biosciences slips despite Q4 beat after deal to sell shares - MSN
Pulse Biosciences stock slips despite Q4 beat (PLSE:NASDAQ) - Seeking Alpha
Pulse Biosciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference - The AI Journal
Pulse Biosciences earnings in focus after clinical data surge - Investing.com Australia
Decoding Pulse Biosciences Inc (PLSE): A Strategic SWOT Insight - GuruFocus
Pulse Biosciences Q4 2025 Earnings Call Transcript - MarketBeat
Pulse Biosciences Inc (PLSE) Q4 2025 Earnings Call Highlights: I - GuruFocus
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results - BioSpace
Pulse Biosciences Q4 Earnings Call Highlights - MarketBeat
Pulse Biosciences, Inc (PLSE) Reports Q4 Loss, Beats Revenue Estimates - Bitget
Pulse Biosciences Shares Fall After Q4 Loss Widens as Clinical Spending Rises and Revenue Remains Limited - AlphaStreet News
Pulse Biosciences to offer securities worth $200 million - marketscreener.com
Pulse Biosciences To Offer Securities Worth $200 Million - TradingView
Pulse Biosciences Establishes New $60 Million ATM Program - TipRanks
Pulse Biosciences (NASDAQ:PLSE) Releases Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
Earnings Flash (PLSE) Pulse Biosciences, Inc. Reports Q4 Revenue $264K, vs. FactSet Est of $150K - marketscreener.com
PLSE: Advanced pivotal clinical programs in AF ablation with rising losses and modest initial revenue - TradingView
Pulse Biosciences Launches $59.98 Million ATM Equity Program With TD Cowen - TradingView
Pulse Biosciences Q4 Earnings Report: What Investors Need to Know - Benzinga
Finanzdaten der Pulse Biosciences Inc-Aktie (PLSE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Pulse Biosciences Inc-Aktie (PLSE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 18 '26 |
Sale |
23.64 |
5,000 |
118,200 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 12 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 13 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 17 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 17 '26 |
Sale |
23.63 |
20,000 |
472,600 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 13 '26 |
Sale |
23.53 |
20,000 |
470,600 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 12 '26 |
Sale |
23.37 |
20,000 |
467,400 |
43,298 |
1.26%
2.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):